What Drugs Should You Not Take With Metronidazole? A Complete Interaction Guide

Metronidazole should not be taken with alcohol, disulfiram, propylene glycol-containing products, or certain anticoagulants without careful medical supervision—these combinations can cause serious adverse reactions ranging from disulfiram-like effects (flushing, nausea, vomiting) to dangerous bleeding when combined with warfarin. The FDA lists multiple contraindicated combinations, and several major interactions require close monitoring or dosage adjustment.

What Is Metronidazole and Why Does It Interact With Other Drugs?

Metronidazole is a nitroimidazole antibiotic and antiprotozoal agent used to treat bacterial infections (particularly anaerobic bacteria like those causing dental infections or diverticulitis), parasitic infections (giardia, trichomoniasis), and inflammatory bowel conditions. It's sold under brand names including Flagyl, MetroGel, and Metrogel-Vaginal.

The reason metronidazole causes so many interactions stems from how your body processes it. The drug is metabolized primarily through liver pathways involving alcohol dehydrogenase and cytochrome P450 enzymes—the same metabolic systems that process alcohol, warfarin, and many other medications. When metronidazole shares these pathways with other drugs, competition occurs, leading to increased drug levels, reduced effectiveness, or toxic accumulation. Additionally, metronidazole's chemical structure allows it to inhibit certain CYP450 enzymes, particularly CYP2C9, which means it can increase blood levels of drugs that depend on this enzyme for breakdown.

Understanding these mechanisms is critical because metronidazole is one of the most commonly prescribed antibiotics worldwide—millions of doses are dispensed annually—yet many patients and some prescribers underestimate the severity of its interactions.

The Most Serious Interactions: What the FDA Says

Alcohol and Propylene Glycol–Containing Products (Contraindicated)

The most famous metronidazole interaction is with alcohol, documented in FDA labeling for over 50 years. When metronidazole and alcohol are combined, patients experience a disulfiram-like reaction—a constellation of intensely unpleasant symptoms including severe abdominal cramps, nausea, vomiting, headaches, flushing, and chest pain. The reaction can begin within minutes of alcohol consumption and may last for several hours.

The mechanism: Both metronidazole and alcohol are metabolized by alcohol dehydrogenase. When metronidazole blocks this enzyme, alcohol accumulates in the bloodstream in the form of acetaldehyde, a toxic metabolite that causes the characteristic disulfiram-like reaction. This is the same reaction deliberately triggered by the drug disulfiram (Antabuse), which is used as a deterrent in alcohol-use disorder treatment.

The FDA contraindication states that patients must avoid all alcohol during metronidazole therapy and for at least 3 days after the last dose. This includes not just alcoholic beverages but also:

• Mouthwash containing alcohol
• Cough syrups with alcohol
• Certain herbal tinctures and supplements
• Some liquid medications (check the label)
• Products containing propylene glycol (an alcohol-like compound)

Propylene glycol, found in some liquid medications, intravenous solutions, and cosmetic products, produces the identical disulfiram-like reaction. This interaction is particularly dangerous in clinical settings where IV propylene glycol-containing medications might be administered without awareness of concurrent metronidazole use.

Disulfiram (Contraindicated)

Patients taking disulfiram (Antabuse) for alcohol-use disorder should not be given metronidazole. The FDA warning states that psychotic reactions have been reported when these drugs are used together, and metronidazole should not be given to patients who have taken disulfiram within the previous two weeks.

The exact mechanism of the psychotic reaction is not fully understood, but both drugs inhibit certain enzyme systems and may accumulate to toxic levels in the central nervous system. Cases have documented acute confusion, hallucinations, and severe behavioral disturbances in alcoholic patients on disulfiram who received metronidazole.

Anticoagulants: Warfarin and Oral Anticoagulants (Major Interaction)

Metronidazole is a potent CYP2C9 inhibitor, and warfarin is metabolized almost entirely by CYP2C9. When these drugs are combined, warfarin blood levels increase significantly, potentiating its anticoagulant effect and increasing INR (International Normalized Ratio) to dangerous levels—placing the patient at risk for life-threatening bleeding.

The FDA requires that patients on warfarin or other oral anticoagulants have their prothrombin time and INR monitored carefully when starting metronidazole. In many cases, the warfarin dose must be reduced by 30–50% during concurrent metronidazole therapy. Similar caution applies to other coumarin anticoagulants like acenocoumarol.

This interaction is particularly common in clinical practice because both drugs address separate medical conditions: a patient might be on warfarin for atrial fibrillation or thromboembolism and then develop a dental abscess or diverticulitis requiring metronidazole. The interaction is not always prevented if the drugs are started at different times—even adding metronidazole weeks into stable warfarin therapy can destabilize INR control.

Busulfan (Contraindicated)

Busulfan is a chemotherapy alkylating agent used in cancer treatment and bone marrow transplant conditioning. Metronidazole increases busulfan plasma concentrations, raising the risk of serious busulfan toxicity including severe mucositis, liver damage, and veno-occlusive disease. This combination should be avoided unless the therapeutic benefit clearly outweighs the risk, and if unavoidable, requires careful monitoring and likely dose adjustment of busulfan.

Dronabinol Oral Solution (Contraindicated)

Dronabinol (Marinol) is a synthetic cannabinoid used for chemotherapy-related nausea. The oral solution contains alcohol as a vehicle. The FDA specifically contraindicates concurrent use with metronidazole due to the alcohol content causing disulfiram-like reactions. If a patient needs both drugs, the recommendation is to discontinue metronidazole at least 14 days before starting dronabinol and to avoid administering dronabinol within 7 days of completing metronidazole therapy.

Mebendazole (Contraindicated)

Mebendazole, an anthelmintic used for parasitic worm infections, should not be combined with metronidazole. No specific mechanism is documented in FDA labels, but the contraindication exists, requiring alternative antiparasitic agents if metronidazole is necessary.

Major Interactions Requiring Monitoring

Mycophenolic Acid and Mycophenolate (Major)

Mycophenolic acid (CellCept, Myfortic) is an immunosuppressant used in transplant patients. Metronidazole may decrease mycophenolic acid concentrations, reducing immunosuppressive efficacy. This creates a clinical dilemma: a transplant patient on mycophenolate who develops a bacterial infection needing metronidazole faces potential transplant rejection if concentrations drop, yet untreated infection also poses grave risk. This combination is not recommended, and alternative antibiotics should be sought. If metronidazole is unavoidable, mycophenolate levels should be monitored and doses may need adjustment.

CYP2C9 Substrate Medications

Beyond warfarin, metronidazole's CYP2C9 inhibition affects other drugs metabolized by this enzyme, including some NSAIDs (ibuprofen, naproxen), certain sulfonylureas (glipizide), and phenytoin. While the interaction may not rise to contraindication level, it warrants monitoring and possible dose adjustment.

Clinical Scenarios: Real-World Examples

Scenario 1: The Transplant Patient With Infection

A 62-year-old woman is 8 years post-kidney transplant on a stable regimen including mycophenolate mofetil (MMF), tacrolimus, and prednisone. She presents to her dentist with a severely infected lower molar requiring extraction. The dentist prescribes metronidazole 500 mg three times daily for anaerobic coverage before the extraction. The patient fills the prescription and takes the first dose.

What should happen: The patient's transplant team should be notified immediately. Although metronidazole is reasonable for dental infection coverage, the combination with mycophenolate requires either (1) choosing an alternative antibiotic such as clindamycin or amoxicillin-clavulanate, or (2) if metronidazole is essential, monitoring mycophenolate levels frequently (potentially daily) and adjusting the dose upward to maintain therapeutic immunosuppression. The FDA labeling specifically states this combination is not recommended, so alternative antibiotics are preferred.

Scenario 2: The Atrial Fibrillation Patient Needing Antibiotic

A 74-year-old man with atrial fibrillation has been stable on warfarin for 3 years with INR consistently 2.0–2.5. He develops acute diverticulitis confirmed by CT imaging and is admitted to the hospital. The infectious disease team, following standard protocol for diverticulitis, starts IV metronidazole 500 mg every 6 hours (in addition to ceftriaxone for aerobic gram-negatives).

What should happen: The prescribing team should check the patient's current medications before starting metronidazole. Upon discovering warfarin, they should (1) order a baseline INR immediately, (2) reduce the warfarin dose by 30–50% (often to 25–50% of baseline), (3) recheck INR every 2–3 days during metronidazole therapy and during the 3-day washout period after stopping it, and (4) have a plan to resume the original warfarin dose once metronidazole is completed and INR restabilizes. Many hospitals use computerized prescriber alerts to flag this interaction, but if those fail, it falls to clinical judgment. Without monitoring, INR can rise to 4.0 or higher, dramatically increasing bleeding risk.

Interactions at a Glance: FDA Severity Ranking

• Contraindicated (Avoid): Alcohol, propylene glycol–containing products, disulfiram, busulfan, dronabinol oral solution, mebendazole
• Major (Close Monitoring Required): Warfarin and oral anticoagulants, mycophenolic acid/mycophenolate, other CYP2C9 substrates (phenytoin, certain sulfonylureas)
• Moderate (Monitor/Consider Alternatives): Lithium (metronidazole may increase lithium levels), certain antifungals, and other medications sharing metabolism pathways

What Patients Should Tell Their Doctor

When prescribed metronidazole, explicitly mention:

• All medications you take, including over-the-counter drugs, supplements, and herbal products
• Whether you are on any blood thinner (warfarin, apixaban, dabigatran, rivaroxaban)
• Whether you take disulfiram or are in treatment for alcohol use disorder
• Any history of psychotic or mental health conditions
• Liver or kidney disease (metronidazole is hepatically metabolized and renally cleared)
• Pregnancy (metronidazole can cross the placenta, though short courses are often considered acceptable)
• All alcohol-containing products you use, including mouthwash and cough syrups

Your pharmacist is also a critical resource—they review all your medications and can catch interactions that busy prescribers might miss. Don't hesitate to ask your pharmacist to verify that metronidazole is safe with your current regimen before you leave the pharmacy.

Management and Prevention: What Doctors Should Do

Healthcare providers prescribing metronidazole should:

• Always perform a complete medication reconciliation, including OTC and herbal products
• Check for contraindications (alcohol, disulfiram, propylene glycol exposure, busulfan)
• For warfarin patients: reduce warfarin dose by 30–50%, order baseline INR, recheck every 2–3 days during therapy
• For mycophenolate patients: strongly consider alternative antibiotics; if metronidazole unavoidable, monitor mycophenolate levels
• Provide explicit written and verbal instructions about alcohol avoidance, including alcohol in medications
• Document the interaction discussion in the medical record
• For longer courses (>7–10 days), consider whether shorter-course alternatives exist

Metronidazole is typically prescribed for 5–10 days for acute infections, so duration is usually finite—this is reassuring because many interactions resolve within days of stopping the drug (though warfarin INR may take 3–7 days to restabilize).

Checking Your Full Medication List

Beyond individual drug-drug interactions, metronidazole can be part of multi-drug combinations that increase risk. For example, a patient on warfarin + metronidazole + an NSAID faces compounded bleeding risk. Using a comprehensive drug interaction checker that reviews your entire medication profile—not just pairwise interactions—is essential.

Metronidazole and warfarin interaction is one of the most clinically significant, but metronidazole and alcohol interaction is perhaps the most commonly encountered in outpatient practice. Similarly, metronidazole and disulfiram interaction is absolutely contraindicated in patients being treated for alcohol use disorder.

Key Takeaways

• Metronidazole is contraindicated with alcohol, disulfiram, propylene glycol products, busulfan, dronabinol oral solution, and mebendazole due to risk of disulfiram-like reactions, psychosis, or severe toxicity.
• Metronidazole significantly increases warfarin and oral anticoagulant levels through CYP2C9 inhibition—warfarin dose reduction and frequent INR monitoring are mandatory when these drugs are combined.
• Always mention all medications (including OTC and herbal products) when prescribed metronidazole, and avoid all alcohol and alcohol-containing products during therapy and for 3 days after completion.
• Mycophenolate patients should use alternative antibiotics if possible; if metronidazole is necessary, mycophenolate levels must be monitored closely.
• A comprehensive drug interaction checker reviewing your entire medication profile is far more reliable than checking interactions one-by-one, especially for patients on multiple medications.

Sources

• FDA Drug Labeling via OpenFDA: open.fda.gov — Metronidazole oral and IV labeling
• National Library of Medicine DailyMed: Metronidazole product information, accessed via dailymed.nlm.nih.gov
• Warfarin (Coumadin) FDA labeling: Interaction with CYP2C9 inhibitors including metronidazole
• Disulfiram (Antabuse) FDA labeling: Contraindication with metronidazole and psychotic reaction risk
• Busulfan (Busulfex) FDA labeling: Increased plasma concentrations with metronidazole
• Mycophenolic Acid (CellCept) FDA labeling: Potential decreased concentrations with metronidazole
• Dronabinol (Marinol) FDA labeling: Alcohol-containing oral solution contraindicated with metronidazole

Your Next Step: Verify Your Medication Safety

If you've been prescribed metronidazole or are already taking it, don't rely on memory or a single source. Use checkdruginteractions.com to enter your complete medication list—all prescriptions, over-the-counter drugs, and supplements—and get a comprehensive safety profile generated from over 250,000 FDA drug labels. Our database is updated regularly and powered by the NIH National Library of Medicine and openFDA, giving you the same clinical-grade data that pharmacists use. Enter your medications now and get peace of mind that your regimen is safe, or identify interactions early before they cause harm.